Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group.
Arjan A van de LoosdrechtWolfgang KernAnna PorwitPeter ValentSharham KordastiEline CremersCanan AlhanCarolien DuetzAlan DunlopWillemijn HoboFrank PreijersOrianne Wagner-BallonNicolas ChapuisMichaela FontenayPeter BettelheimLisa Eidenschink-BrodersenPatricia FontUlrika JohanssonMichael R LokenJeroen G Te MarveldeSergio MatarrazKiyoyuki OgataUta OelschlaegelAlberto OrfaoKatherina PsarraDolores SubiráDenise A WellsMarie Christine BeneMatteo G Della PortaKate BurburyFrauke BellosVincent H J van der VeldenTheresia M WestersLeonie SaftRobin IrelandPublished in: Cytometry. Part B, Clinical cytometry (2021)
This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.